妊娠及产后丁丙诺啡与美沙酮治疗中断的比较:全国队列研究
该全国性队列研究利用美国医疗补助数据,比较了妊娠早期启动美沙酮或舌下丁丙诺啡(含或不含纳洛酮)治疗阿片类物质使用障碍的孕妇在孕期及产后1年内的治疗中断情况。结果显示,丁丙诺啡启动者的治疗中断风险显著高于美沙酮启动者,但两种治疗的中断率均较高。
要点
- 妊娠早期启动丁丙诺啡者孕期中断治疗风险显著高于美沙酮(加权HR=1.41)。
- 产后1年内丁丙诺啡中断风险仍高于美沙酮(HR=1.37)。
- 丁丙诺啡/纳洛酮复方制剂的中断风险高于丁丙诺啡单药。
核心结论
- 妊娠早期启动舌下丁丙诺啡的患者比启动美沙酮者更可能中断治疗,但两种治疗的中断率均较高。
研究设计与样本
- 全国性队列研究,使用美国医疗补助数据,纳入妊娠早期启动美沙酮或舌下丁丙诺啡(含或不含纳洛酮)治疗阿片类物质使用障碍的孕妇。
- 共纳入696例美沙酮启动者和1538例丁丙诺啡启动者。
- 主要结局为治疗中断(治疗间隙≥60天),采用倾向评分重叠加权Cox比例风险回归估计风险比。
主要发现
- 孕期治疗中断率:丁丙诺啡32.8% vs. 美沙酮25.6%,加权HR=1.41(95% CI=1.15, 1.72)。
- 产后1年内治疗中断率:丁丙诺啡58.8% vs. 美沙酮49.0%,HR=1.37(95% CI=1.19, 1.57)。
- 丁丙诺啡/纳洛酮复方亚组:孕期HR=1.73(95% CI=1.36, 2.19),产后1年内HR=1.56(95% CI=1.30, 1.86)。
- 丁丙诺啡单药亚组:孕期HR=1.14(95% CI=0.90, 1.46),产后1年内HR=1.23(95% CI=1.04, 1.46)。
- 敏感性分析中改变治疗间隙定义,结果一致。
临床怎么用
- 对于妊娠期阿片类物质使用障碍患者,选择丁丙诺啡治疗时应加强治疗保留支持。
- 应识别并解决影响孕妇治疗保留的障碍,以降低中断风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of pregnant patients with opioid use disorder with methadone or buprenorphine is crucial for maternal and neonatal safety. While several clinical trials have demonstrated higher treatment discontinuation rates for buprenorphine compared with methadone outside of pregnancy, evidence during pregnancy and the postpartum period is limited. The authors compared treatment discontinuation between buprenorphine and methadone during pregnancy and over follow-up through 1 year postpartum. METHODS: This was a cohort study, using nationwide Medicaid data, of pregnant patients who initiated methadone or transmucosal buprenorphine (with or without naloxone) for opioid use disorder during the first trimester. The primary outcome was treatment discontinuation, defined as a treatment gap ≥60 days; alternative definitions for discontinuation were explored in sensitivity analyses. Hazard ratios were estimated using Cox proportional hazards regression with propensity score overlap weighting to control for confounding. Subgroup analyses were conducted, stratified by buprenorphine alone versus the buprenorphine/naloxone combination, each compared to methadone. RESULTS: Overall, 696 pregnant patients were identified who initiated methadone treatment and 1,538 who initiated buprenorphine treatment in the first trimester. Compared to methadone initiators, buprenorphine initiators were more likely to discontinue treatment during pregnancy (32.8% for buprenorphine vs. 25.6% for methadone; weighted hazard ratio=1.41, 95% CI=1.15, 1.72) and through 1 year postpartum (58.8% vs. 49.0%; hazard ratio=1.37, 95% CI=1.19, 1.57). For patients initiating the buprenorphine/naloxone combination, the hazard ratio was 1.73 (95% CI=1.36, 2.19) during pregnancy and 1.56 (95% CI=1.30, 1.86) through 1 year postpartum. For patients initiating buprenorphine alone, the hazard ratios were 1.14 (95% CI=0.90, 1.46) and 1.23 (95% CI=1.04, 1.46), respectively. Varying the treatment gap used to define discontinuation in sensitivity analyses yielded consistent results. CONCLUSION: Pregnant patients initiating transmucosal buprenorphine during early pregnancy were more likely to discontinue treatment than those initiating methadone, but treatment discontinuation was high for both treatments. The study findings highlight the importance of identifying and addressing barriers to treatment retention among pregnant patients with opioid use disorder.
引用
- Lin C-WG, Bateman BT, Straub L, et al. Buprenorphine and Methadone Discontinuation During Pregnancy and the Postpartum Period: A Nationwide Cohort Study. Am J Psychiatry. 2025. PMID: 40859701. doi:10.1176/appi.ajp.20241127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。